Histone deacetylase inhibitors in cancer treatment

Anti-Cancer Drugs

Volumn 13, Issue 1, 2002, Pages 1-13

  Vigushin, David M ^a   Coombes, R Charles ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Acetylation; Differentiation; Gene transcription; Histone deacetylase

Indexed keywords

ANTINEOPLASTIC AGENT; APICIDIN; BUTYRIC ACID; DEPSIPEPTIDE; DEPUDECIN; ESTROGEN RECEPTOR; FR 901228; HISTONE DEACETYLASE INHIBITOR; LYSINE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXAMFLATIN; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 1; TRAPOXIN; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CELL ACTIVITY; CHROMATIN STRUCTURE; CLINICAL TRIAL; DRUG MECHANISM; GENE EXPRESSION REGULATION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION INITIATION;

ACETYLATION; ANIMALS; APOPTOSIS; CLINICAL TRIALS; ENZYME INHIBITORS; GENE EXPRESSION; HISTONE DEACETYLASES; HISTONES; HUMANS; NEOPLASMS;

EID: 0036176617     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200201000-00001     Document Type: Review

References (136)

1. What's up and down with histone deacetylation and transcription?
2. Histone acetylation: Chromatin in action
3. Transcriptional control. Sinful repression
4. Histone acetylation and transcriptional regulatory mechanisms
5. Histone acetylases and deacetylases in cell proliferation
6. Histone acetylation in chromatin structure and transcription
7. Covalent modifications of histones: Expression from chromatin templates
8. Control of histone modifications
9. Roles of histone acetyltransferases and deacetylases in gene regulation
10. Regulation of gene expression by transcription factor acetylation
11. Tetrahymena histone acetyltransferase A: A homolog to yeast Gcn5p linking histone acetylation to gene activation
12. The transcriptional coactivators p300 and CBP are histone acetyltransferases
13. The TAF(II)250 subunit of TFIID has histone acetyltransferase activity
14. Steroid receptor coactivator-1 is a histone acetyltransferase
15. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p
16. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression
17. Characterization of a human RPD3 ortholog, HDAC3
18. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor
19. HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription
20. HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor
21. Three proteins define a class of human histone deacetylases related to yeast Hda1p
22. Active maintenance of mHDA2/mHDAC6 histone-deacetylase in the cytoplasm
23. Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression
24. A dynamic role for HDAC7 in MEF2-mediated muscle differentiation
25. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
26. Structure of the histone deacetylase SIRT2
27. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression
28. Histone deacetylase activity is required for full transcriptional repression by mSin3A
29. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression
30. Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex
31. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription
32. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex
33. Histone deacetylase directs the dominant silencing of transcription in chromatin: Association with MeCP2 and the Mi-2 chromodomain SWI/SNF ATPase
34. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a
35. Histone deacetylases, transcriptional control, and cancer
36. Histone deacetylases specifically down-regulate p53-dependent gene activation
37. Regulation of activity of the transcription factor GATA-1 by acetylation
38. Acetylation of general transcription factors by histone acetyltransferases
39. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo
40. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity
41. Retinoblastoma protein recruits histone deacetylase to repress transcription
42. Retinoblastoma protein represses transcription by recruiting a histone deacetylase
43. HDAC4 deacetylase associates with and represses the MEF2 transcription factor
44. Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals
45. The Mad protein family links transcriptional repression to cell differentiation
46. c-Myc target genes involved in cell growth, apoptosis, and metabolism
47. Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor
48. Role of the retinoblastoma protein in the pathogenesis of human cancer
49. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
50. Role of the histone deacetylase complex in acute promyelocytic leukaemia
51. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia
52. PML/RAR alpha fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype
53. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL
54. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression
55. Role of histone deacetylases in acute leukemia
56. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation
57. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex
58. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells
59. A new antifungal antibiotic, trichostatin
60. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A
61. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
62. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
63. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase
64. Mass spectrometric determination of amino acid sequence in Cyl-2, a novel cyclotetrapeptide from Cylindrocladium scoparium
65. The structure and conformation of HC-toxin
66. Studies on WF-3161, a new antitumor antibiotic
67. Isolation and structural clarification of chlamydocin
68. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor
69. Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase
70. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors
71. Butyrate as a differentiating agent: Pharmacokinetics, analogues and current status
72. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
73. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase
74. Trichostatin C, a glucopyranosyl hydroxamate
75. Effects of trichostatins on differentiation of murine erythroleukemia cells
76. Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function
77. Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells
78. 2 phases by trichostatin A
79. Different accessibilities in chromatin to histone acetylase
80. Effects of sodium butyrate, a new pharmacological agent, on cells in culture
81. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents
82. WAF1/Cip1 and gelsolin
83. Depudecin, a microbial metabolite containing two epoxide groups, exhibits anti-angiogenic activity in vivo
84. Synthesis and cellular characterization of the detransformation agent, (-)-depudecin
85. Potent cytodifferentiating agents related to hexamethylene-bisacetamide
86. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
87. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin
88. Identification of a new family of higher eukaryotic histone deacetylases. Coordinate expression of differentiation-dependent chromatin modifiers
89. Cellular and molecular changes in 3T3 cells transformed spontaneously or by DNA transfection
90. Changes in microfilament organization and surface topogrophy upon transformation of chick embryo fibroblasts with Rous sarcoma virus
91. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines
92. Predominant induction of gelsolin and actin-binding protein during myeloid differentiation
93. Gelsolin: A candidate for suppressor of human bladder cancer
94. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells
95. 1 arrest and long-term induction of Cip1 in normal human fibroblasts
96. WAF/CIP1 in p53-independent manner
97. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites
98. Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sites
99. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells
100. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation
101. DNA damage activates p53 through a phosphorylation-acetylation cascade
102. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage
103. Acetylation and modulation of erythroid Kruppel-like factor (EKLF) activity by interaction with histone acetyltransferases
104. Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase
105. DNA associated with hyperacetylated histone is preferentially digested by DNase I
106. Carboxypeptidase A3 (CPA3): A novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells
107. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): Dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway
108. Involvement of histone hyperacetylation in triggering DNA fragmentation of rat thymocytes undergoing apoptosis
109. Interaction between dexamethasone and butyrate in apoptosis induction: Non-additive in thymocytes and synergistic in a T cell-derived leukemia cell line
110. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma
111. IGF-II enhances trichostatin A-induced TGFbeta1 and p21(Waf1, Cip1, sdi1) expression in Hep3B cells
112. Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis
113. Trichostatin A inhibits both ras-induced neurite outgrowth of PC12 cells and morphological transformation of NIH3T3 cells
114. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors
115. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex
116. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation
117. The inactive X chromosome in female mammals is distinguished by a lack of histone H4 acetylation, a cytogenetic marker for gene expression
118. DNA methylation models histone acetylation
119. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters
120. DNA methyltransferase Dnmt1 associates with histone deacetylase activity
121. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci
122. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
123. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition
124. Comparison between the effect of butyric acid and its prodrug pivaloyloxy-methylbutyrate on histones hyperacetylation in an HL-60 leukemic cell line
125. Doxorubicin and a butyric acid derivative effectively reduce levels of BCL-2 protein in the cells of chronic lymphocytic leukemia patient
126. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice
127. In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD/Shi-scid/scid mice
128. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate
129. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells
130. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA)
131. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity
132. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer
133. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors
134. Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child
135. Marine organisms and other novel natural sources of new cancer drugs
136. Inhibitors of histone deacetylase are potentially effective anticancer agents